241499-17-2

Usage

Uses

Used in Pharmaceutical Industry:
[1-(4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine is used as a potential active pharmaceutical ingredient for the development of new drugs due to its unique structural features and the possibility of interacting with various biological targets.
Used in Organic Chemistry:
In the field of organic chemistry, [1-(4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine can be used as a building block or intermediate in the synthesis of more complex molecules, potentially leading to the creation of novel compounds with specific properties and applications.
Used in Medicinal Chemistry:
[1-(4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine may be utilized in medicinal chemistry for the design and optimization of drug candidates, taking advantage of its structural diversity and the potential for modifications to enhance its pharmacological properties.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 917-92-0 3,3-Dimethylbut-1-yne 
• 100-10-7 4-dimethylamino-benzaldehyde 
• 241499-55-8 [4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-piperidin-4-yl-amine 
• 241499-54-7 4-[[4-(3,3-Dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester 
• 241499-51-4 [4-(3,3-dimethyl-butyl)-phenyl]-carbamic acid tert-butyl ester 
• 241499-50-3 [4-(3,3-dimethyl-but-1-ynyl)-phenyl]-carbamic acid tert-butyl ester 
• 540-37-4 p-aminoiodobenzene 
• 159217-89-7 N-Boc-4-iodoaniline 
• 241499-53-6 4-[4-(3,3-Dimethyl-butyl)-phenylamino]-piperidine-1-carboxylic acid tert-butyl ester 
• 241499-52-5 4-(3,3-dimethyl-butyl)-phenylamine 

Relevant academic research and scientific papers

Heterocyclic substituted aniline calcium channel blockers

The present invention provides compounds that block calcium channels having the Formula I shown below. STR1The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, epilepsy, asthma, amyotrophic lateral sclerosis, or pain and to pharmaceutical compositions that contain the compounds of Formula I.

The discovery of [1-(4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phenyl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel blocker with oral activity for analgesia

Our drug discovery efforts for N-type calcium channel blockers in the 4-piperidinylaniline series led to the discovery of an orally active analgesic agent 26. 1-[4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine (26) showed high affinity to functionally block N-type calcium channels (IC50=0.7 μM in the IMR32 assay) and exhibited high efficacy in the anti-writhing analgesia test with mice (ED50=12 mg/kg by po and 4 mg/kg by iv). In this report, the rationale for the design, synthesis, biological evaluation, and pharmacokinetics of this series of blockers is described. Copyright (C) 2000 Elsevier Science Ltd.